593 related articles for article (PubMed ID: 17543076)
1. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
4. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
5. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.
Moinfar F; Okcu M; Tsybrovskyy O; Regitnig P; Lax SF; Weybora W; Ratschek M; Tavassoli FA; Denk H
Cancer; 2003 Aug; 98(4):703-11. PubMed ID: 12910513
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
Serra C; Vizoso F; Lamelas ML; Rodríguez JC; González LO; Merino AM; Baltasar A; Pérez-Vázquez MT; Medrano J
Int J Surg Investig; 2000; 2(3):183-92. PubMed ID: 12678518
[TBL] [Abstract][Full Text] [Related]
8. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
9. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
10. C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.
Diallo R; Rody A; Jackisch C; Ting E; Schaefer KL; Kissler S; Karn T; Geddert H; Engels K; Kaufmann M; Gabbert HE; Shroyer KR; Poremba C
Hum Pathol; 2006 Feb; 37(2):205-11. PubMed ID: 16426921
[TBL] [Abstract][Full Text] [Related]
11. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
[TBL] [Abstract][Full Text] [Related]
13. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
14. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
15. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component.
Yu KD; Wu LM; Liu GY; Wu J; Di GH; Shen ZZ; Shao ZM
Ann Surg Oncol; 2011 May; 18(5):1342-8. PubMed ID: 21042943
[TBL] [Abstract][Full Text] [Related]
16. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
17. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
[TBL] [Abstract][Full Text] [Related]
18. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
19. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
20. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
